What is SparingVision?
SparingVision is a specialized genomic medicines company dedicated to translating pioneering scientific research into effective, vision-saving treatments. The firm operates at the intersection of advanced biotechnology and ophthalmology, focusing on the development of innovative therapies for patients suffering from retinal degenerative diseases. By targeting the underlying genetic causes of vision loss, SparingVision aims to provide transformative solutions that go beyond symptom management, offering the potential for long-term therapeutic impact. The company's market position is bolstered by a robust intellectual property portfolio and a strategic focus on high-impact, scalable medical interventions.
How much funding has SparingVision raised?
SparingVision has raised a total of $130.5M across 3 funding rounds:
Grant
$2.8M
Series A
$52.7M
Series B
$75M
Grant (2019): $2.8M with participation from European EIC Accelerator
Series A (2020): $52.7M led by Jeito Capital, University of Pittsburgh Medical Centre Enterprise, 4BIO Capital, Ysios Capital, Foundation Fighting Blindness, and Bpifrance
Series B (2022): $75M supported by University of Pittsburgh Medical Center Enterprise, Retinal Degeneration Fund, Ysios Capital, Bpifrance, Jeito, and 4BIO Capital
Key Investors in SparingVision
Ysios Capital
Ysios Capital is a leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide, providing resources to ventures focused on developing novel therapies for high unmet medical needs.
Bpifrance
Founded in 2012, Bpifrance finances companies at each stage of their development with credit, guarantees, and equity, supporting innovation projects and international expansion.
Retinal Degeneration Fund
The Retinal Degeneration Fund is dedicated to accelerating life-changing outcomes for individuals affected by retinal degenerations through strategic investments in therapeutic companies developing innovative solutions.
What's next for SparingVision?
With the recent infusion of capital, SparingVision is poised to advance its lead candidates through critical clinical milestones. The strategic roadmap emphasizes the scaling of manufacturing capabilities and the expansion of its research and development infrastructure to support multi-site clinical trials. As the company moves deeper into its lifecycle, the focus will shift toward regulatory engagement and the establishment of commercial partnerships to ensure that its novel therapies reach patients efficiently. The continued support from specialized life sciences investors provides the financial runway required to navigate the complexities of late-stage drug development and to maintain a competitive edge in the rapidly evolving field of genomic medicine.
See full SparingVision company page
